---
title: "Scienture Holdings Stock Climbs 31% After GPO Agreements For REZENOPY Naloxone Spray"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278743200.md"
description: "Shares of Scienture Holdings, Inc. (SCNX) surged 31% after the company secured multiple Group Purchasing Organization agreements for its REZENOPYTM naloxone nasal spray. The stock is currently trading at $0.51, having opened at $0.61 and reached a high of $0.64. These agreements are expected to enhance the company's access to over 5,000 healthcare facilities, potentially covering 60% of the U.S. institutional market."
datetime: "2026-03-11T14:50:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278743200.md)
  - [en](https://longbridge.com/en/news/278743200.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278743200.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278743200.md) | [繁體中文](https://longbridge.com/zh-HK/news/278743200.md)


# Scienture Holdings Stock Climbs 31% After GPO Agreements For REZENOPY Naloxone Spray

Add  as your preferred news source on Google

 Add Now

Shares of Scienture Holdings, Inc. (SCNX) are moving up about 31 percent on Wednesday morning trading after the company formalized multiple commercial Group Purchasing Organization agreements for REZENOPYTM (naloxone HCl) Nasal Spray 10 mg.

The company's shares are currently trading at $0.51 on the Nasdaq, up 31.40 percent. The stock opened at $0.61 and has climbed as high as $0.64 so far in today's session. Over the past year, it has traded in a range of $0.37 to $3.17.

The agreements are expected to expand the company's institutional reach, providing access to more than 5000 healthcare facilities representing potential penetration into approximately 60% of the U.S. institutional market.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Scienture Holdings, Inc. (SCNX.US)](https://longbridge.com/en/quote/SCNX.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/en/news/281015927.md)
- [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/en/news/281051985.md)
- [Arcutis Reports New Positive Phase 2 Results For ZORYVE Cream In Infant Atopic Dermatitis](https://longbridge.com/en/news/280971278.md)
- [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/en/news/281024362.md)
- [Bayer Announces Approval Of New Indication For Kerendia In The EU](https://longbridge.com/en/news/280969658.md)